Foci Pharmaceutical(SZ:002644) Mei Ri Jing Ji Xin Wen·2025-10-17 11:30Core Viewpoint - The company, Foci Pharmaceutical, is strategically investing in the radioactive isotope drug sector by increasing its stake in Kejin Technology, aiming to enhance its core competitiveness and align with national policies and market demands [1][12][18]. Company Overview - Foci Pharmaceutical, established in 1929, has a long history as a traditional Chinese medicine manufacturer, focusing on proprietary Chinese medicine and health products [6][8]. - The company has a comprehensive product line with 467 drug approval numbers and various dosage forms, but has faced challenges in revenue growth and profitability in recent years [9][11]. Investment Details - Foci Pharmaceutical will invest 20 million yuan to acquire a 4.911% stake in Kejin Technology, which is involved in the production and research of medical isotopes [1][12]. - The total financing for this investment round reached 373 million yuan, with participation from several institutions, including the Chinese Academy of Sciences [5][12]. Market Potential - The radioactive drug market in China is projected to grow to 26 billion yuan by 2030, indicating significant potential for future revenue generation [15][14]. - The investment aligns with the company's strategy to diversify its business and enhance its resilience against market fluctuations [18]. Strategic Implications - This investment allows Foci Pharmaceutical to secure a position in the upstream segment of the radioactive drug industry, which is characterized by high technical barriers and substantial research and development requirements [18][19]. - The company aims to leverage its investment to strengthen its influence in the innovative drug sector and potentially enhance its market presence [19][21].